Only 1 in 25 oncology clinical trials had minority patientsONCY was one of those companies which included minority patients in its clinical trial data with Adlai Nortye running a pelareorep bridging study in China on a Chinese population of patients in metastatic breast cancer that was designed to align with ONCY's IND-213 and Bracelet-1 studies.
https://endpts.com/only-1-of-25-cancer-drug-developers-fairly-included-minority-patients-over-five-year-window-bmj-analysis-finds/
https://www.prnewswire.com/news-releases/oncolytics-biotech-partner-adlai-nortye-advances-chinese-bridging-trial-of-pelareorep-paclitaxel-combination-treatment-in-breast-cancer-to-final-dosing-cohort-301509468.html